2016 American Transplant Congress Archives - Page 180 of 180

Earlier Repletion of Lymphocytes After Alemtuzumab Induction Is Associated with a Lower Incidence of Infection Following Renal Transplantation.

M. Willicombe, D. Goodall, A. McLean, D. Taube.
Early De Novo DSA with T Cell Mediated Rejection (TCMR) Is Associated with Allograft Dysfunction with Chronic Injury.

A. Cherukuri, R. Mehta, P. Sood, A. Zeevi, S. Hariharan, D. Rothstein.
Early Alloantibody Responses Against Donor MHC Class I and Class II Molecules Are Differentially Affected by Prolonged Cold Ischemia Storage of Renal Allografts.

V. Gorbacheva, R. Fan, W. Baldwin, A. Valujskikh.
Early Changes to Kidney Distribution Under the New Kidney Allocation System.

A. Massie,¹ X. Luo,¹ B. Lonze,¹ N. Desai,¹ A. Bingaman,² M. Cooper,³ D. Segev.¹
Early Conversion to Everolimus in De Novo Renal Transplant Recipients: Incidence of Viral Infections in the Randomized-Controlled ELEVATE Study.

H. Hirsch,¹ J. De Fijter,¹ M. van der Giet,¹ M. Zeier,¹ J. Pascual,¹ Y. Avihingsanon,¹ P. Lopez,² J. Aguilar-Sanchez,² J. Kochuparampil,² Z. Wang,³ H. Holdaas,¹ J. Cruzado.¹
Early Enteral Feeding After Living Donor Liver Transplantation Prevents Infectious Complications: A Prospective Pilot Study.

J. Kim,¹ D. Sinn,² S. Lee,¹ G.-S. Choi,¹ J. Park,¹ C. Kwon,¹ S. Kim,¹ J.-W. Joh,¹ S.-K. Lee.¹
Early Hospital Readmisison Among Older Kideny Transplant Recipients.

E. King, L. Kucirka, M. McAdams-DeMarco, F. Al-Ammary, D. Segev.
Early Hospital Readmission After Kidney Transplantation: Seasonality, Causes and Prognosis.

M. Tavares, M. Cristelli, L. Viana, M. de Paula, H. Silva Junior, J. Medina Pestana.
Early Hospital Readmission Among Immunologically Vulnerable Kidney Transplantation Recipients.

E. King, B. Orandi, S. Bae, X. Luo, D. Segev.
Early Hospital Readmission Following Kidney Re-Transplantation.

E. King, B. Orandi, S. Bae, X. Luo, D. Segev.
Early Hospital Readmission Following Pediatric Kidney Transplantation.

E. King, L. Kucirka, M. McAdams-DeMarco, S. Bae, D. Segev.
Early Impact of the New Kidney Allocation System (KAS) in Highly Sensitized Patients.

D. Mompoint-Williams, R. Gaston, G. Jeremy, J. Locke, V. Kumar.
Early Onset Acute Antibody Mediated Rejection (ABMR) Is More Common in Female Than in Male Recipients of a Living Unrelated Donor (LURD) Renal Transplant and Is Associated with the Presence of Preformed Donor Specific Antibodies (DSA).

D. Soonawala,¹ K. Groeneweg,¹ F. van der Toorn,¹ S. Heidt,² D. Roelen,² F. Claas,² J. de Fijter.¹
Early Onset Hyperuricemia Is a Prognostic Marker for Kidney Allograft Dysfunction.

M. Han,¹ S. Yang,² I. Jung,³ S.-K. Park,⁴ Y. Kim,⁵ D. Han,⁵ Y. Kim,¹ S. Kim,⁶ J. Lee.⁷
Early Post Renal Transplant aHUS in Patients with Heterozygous CFHR3-CFHR1 Deletion.

S. Rhazouani, A. Malone, T. Alhamad, T. Maw, D. Brennan, R. Delos Santos.
Early Post-Transplant Immunosuppression (IS) Withdrawal – Final Outcomes of the ITN030ST AWISH Study.

A. Shaked,¹ S. Feng,² J. Punch,³ J. Reyes,⁴ J. Levitsky,⁵ G. Klintmalm,⁶ H. Kopetskie,⁷ M. DesMarais,² A. Priore,⁸ N. Bridges,⁸ P. Sayre.²
Early Post-Transplant Patient, Graft Survival and Rejection Rates Under KAS.

A. Kucheryavaya, D. Stewart, D. Klassen.
Early Posttransplant Complications Following Abo-Incompatible Kidney Transplantation.

L. Rostaing,^1,2,3 A. Allal,¹ H. Naciri Benami,¹ Z. Abdulrahman,¹ L. Esposito,¹ F. Sallusto,¹ N. Doumerc,¹ X. Game,¹ B. Debiol,¹ N. Congy,¹ N. Kamar.^1,3,4
Early Proteomic Predictors of Late Chronic Kidney Disease in Liver Transplant Recipients.

J. Levitsky,¹ S. Asrani,² L. Zhao,¹ M. Abecassis,¹ L. Jennings,² G. Klintmalm.²
Early Steroid Withdrawal in African American Kidney Transplant Recipients: A Propensity Score Matching Analysis.

D. Taber, M. Gebregziabher, T. Srinivas, K. Chavin, P. Baliga, L. Egede.
Early Tacrolimus Exposure in Patients Treated De Novo with Once-Daily Tacrolimus After Liver Transplantation: Relationship with Acute Rejection and Long-Term Outcome.

M. Gastaca, A. Valdivieso, J. Bustamante, P. Ruiz, J. Fernandez, A. Ventoso, M. Testillano, I. Palomares, M. Prieto, P. Salvador, A. Matarranz, M. Suarez, J. Ortiz de Urbina.
Eary Use of Statins Associated with Improved Death-Censored Graft Survival Following Kidney Transplant.

T. Horwedel,¹ D. Brennan,² K. Lentine,³ J. Hagopian.¹
EBV Sero-Positivity Does Not Reduce the Risk for EBV Viremia and/or Post-Transplant Lymphoproliferative Disorder (PTLD) in Patients (Pts) Receiving Belatacept (CTLA4Ig).

J. Choi, B. Shin, J. Kahwaji, S. Ge, D. Thomas, A. Vo, O. Galera, R. Villicana, A. Peng, S. Jordan, M. Toyoda.
Economic Analysis of Survival for Patients Undergoing Kidney Transplant in a Philanthropic Hospital of Sao Paulo, Brazil.

A. Matos,¹ D. Malheiros,² S. Morgado,¹ L. Requiao-Moura,¹ A. Kanamura,³ M. Cendoroglo,³ O. Pavao Santos,³ A. Pacheco-Silva.¹
Eculizumab for Chronic Antibody-Mediated Injury in Kidney Transplant Recipients: A Randomized-Controlled Trial.

S. Kulkarni,¹ N. Kirkiles-Smith,² Y. Deng,³ R. Formica,⁴ M. Gilbert,⁵ V. Broeckner,⁶ L. Bow,¹ J. Pober.²
Effect of Adipose Tissue-Derived Mesenchymal Stem Cells in a Rat Model of Chronic Renal Allograft Rejection.

R. Pepineli, F. Silva, P. Gouveia, G. Tavora, S. Gomes, I. Noronha.
Effect of Angiotensin Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blockade (ARB) Exposure on Intragraft Gene Expression of Kidney Transplant Patients.

C. Suarez-Fuentes,^1,2,4 P. O Broin,³ Y. Bao,¹ E. Akalin.^1,2
Effect of Baseline Co-Morbidity on Mortality in Living Kidney Donors – 10 Year UK Cohort Study.

N. Krishnan,¹ L. Bradbury,² N. Raymond.¹
Effect of Baseline Proteinuria on Long- and Short-Term Outcomes in Live Kidney Donors – 10 Year U.K Cohort Study.

N. Krishnan,¹ L. Bradbury,² N. Raymond.¹
Effect of Complement Inhibition Therapy (Eculizumab) in Patients with C1q-Binding Donor-Specific Anti-HLA Antibodies: A Molecular Appraisal.

C. Lefaucheur,¹ L. Hidalgo,² J. Reeve,² D. Viglietti,¹ C. Gosset,¹ O. Aubert,³ C. Ulloa,³ C. Legendre,³ D. Glotz,¹ P. Halloran,² A. Loupy.³
Effect of Conversion to mTOR Inhibition on Allograft Fibrosis in Pediatric Liver Transplantation.

R. Fischer,¹ S. Foster,² A. Kats,¹ W. Andrews,¹ R. Hendrickson,¹ J. Daniel.¹
Effect of Donor-Recipient Gender Mismatch in Liver Transplant Recipients: A Post-Hoc Analysis of the H2304 Study.

L. Fischer, P. de Simone, G. Dong, P. Lopez, P. Bernhardt, F. Saliba.
Effect of Early Tacrolimus Trough Variability on Graft Outcomes in Lung Transplantation.

K. Boyle, M. Moranville, P. Shah.
Effect of Inflammation on Concentration of Intracellular Tacrolimus.

E. Bae,¹ S. Yang,² S. Han,¹ J.-Y. Park,¹ H. Lee,¹ Y. Kim.¹
Effect of Isolated Intraperitoneal Sirolimus Treatment on the Kidneys of C57BL/6 Mice.

B. Kim,^1,3 Y. Cho,³ H. Lee,³ D. Joo,^2,3 K. Huh,^2,3 M. Kim,^2,3 Y. Kim.^2,3
Effect of Modifying Life Support Withdrawal Practices on Outcomes of Donation After Circulatory Death in Liver Transplantation: A Meta-Analysis.

Y. Cao,^1,2 S. Shahrestani,³ H. Chew,^2,4 M. Crawford,⁵ P. Macdonald,^1,2,4 J. Laurence,^3,5,7 W. Hawthorne,^3,6 K. Dhital,^1,2,4 H. Pleass.^3,5,6
Effect of mTOR Inhibitors on the Risk of Cancer Development After Kidney Transplantation in Chinese Population.

C.-C. Kao,¹ J.-S. Liu,² M.-H. Lin,² F.-C. Chang,¹ Y.-C. Lin,¹ H.-H. Chen,¹ T.-W. Chen,¹ C.-C. Hsu,² M.-S. Wu.¹
Effect of Pylorus Preservation Procedure on Patient and Graft Outcome in Total Pancreatectomy with Islet Autotransplantation.

R. Shahbazov,¹ A. Dabous,² G. Yoshimatsu,² H. Fernandez,² G. Saracino,² B. Naziruddin,² N. Onaca,² P. Kim,² M. Levy.³
Effect of Telehealth Monitoring on Early Hospital Readmission After Renal Transplantation.

K. Noon,¹ N. Sarabu,¹ J. Augustine,¹ D. Hricik,¹ B. Deleva,¹ K. Woodside,² M. Aeder,¹ J. Foote,¹ A. Bruno,¹ K. Walsh,¹ M. Johnston,¹ V. Humphreville,¹ E. Sanchez.¹
Effect on Endothelial function when Hyperglycemia Is Reversed by Single Pancreas Transplantation.

T. Halden,^1,2 I. Eide,^1,2 D. Dahle,¹ A. Åsberg,^1,3 A. Reisæter,¹ T. Jenssen,^1,4 A. Hartmann.^1,2
Effects of Immunosuppression and Sun Exposure on Immune Cell Populations in Skin and Blood of Kidney Transplant Recipients.

M. Burke,¹ L. Nahum,⁴ N. Isbel,¹ R. Carroll,³ H. Soyer,¹ R. Francis,¹ J. Bridge,¹ C. Staatz,² J. Wells.¹
Efficacy and Renal Function in Kidney Transplant Recipients Receiving Tacrolimus (TAC)-Based Immunosuppressive Regimens in Combination with Everolimus (EVR) versus Mycophenolate (MPA).

A. Brigido, H. Tedesco, C. Felipe, M. Cristelli, M. Franco, J. Medina-Pestana.
Efficacy and Safety of Direct Antiviral Agents (DAA)-Based Therapies for Hepatitis C Virus (HCV) Infection in Kidney Transplant (KT) Recipients.

M. Fernandez Ruiz,¹ A. García Santiago,² N. Polanco Fernandez,² R. Muñoz,³ A. Hernandez,² E. González Monte,² V. Mercado,² I. Fernández,³ J. Aguado,¹ M. Praga,² A. Andrés.²
Efficacy of Nine National Policies Reimbursing and Incentivizing Live Organ Donation.

V. Apte, S. Fry-Revere.
Elderly Kidney Transplant Recipients Need Optimized Immunosuppression According to Comorbidity and Infection.

E. Kang,¹ S. Park,¹ S. Park,¹ S. Yang,² I. Jung,³ S.-K. Park,⁴ Y. Kim,⁵ D.-J. Han,¹ Y. Kim,¹ J. Lee.⁶
Elevated De Novo Donor Specific Antibody After Alemtuzumab Induction in Renal Transplant Recipients.

K. Fabbri, J. Descourouez, M. Jorgenson, R. Redfield.
Elevated Intragraft Expression of Innate Immunity and Cell Death-Related Markers Characterizes Deceased Donor Conditions and Is a Risk Factor for Adverse Graft Outcome.

M. Eikmans,¹ J. Yang,¹ G. Haasnoot,¹ C. van Kooten,² M. Mallat,² H. de Fijter,² I. Bajema,³ F. Claas.¹
Elevated Lung Shunt Fraction as an Independent Predictor of Local Disease Progression and Metastasis in Hepatocellular Carcinoma.

T. Sandow,¹ D. DeVun,¹ P. Gulotta,¹ H. Bohorquez,² D. Kirsch.¹
Elevated Urinary 11-Dehydrothromboxane B2 Is Associated with Increased Bleeding Risk in Left Ventricular Assist Device Patients.

W. Schultz,⁴ A. Pekarek,³ R. Cole,¹ A. Duncan,⁵ S. Laskar,¹ A. Smith,¹ D. Nguyen,² J. Vega, D. Gupta.¹
Elevation of Peripheral IL-6 in Kidney Transplant Recipients with Antibody Mediated Rejection.

N. Wilson, A. Djamali, R. Redfield.
Eliminating Xenoantigen Expression on Swine Red Blood Cells.

Z.-Y. Wang,¹ G. Martens,¹ R. Blankenship,¹ R. Sidner,¹ P. Li,¹ J. Estrada,¹ M. Tector,² A. Tector.^1,3
Elucidating Clinical Factors Implicated in Primary Graft Dysfunction After Heart Transplantation.

R. Quintana-Quezada, I. Rajapreyar, Y. Yeh, S. Choi, I. Gregoric, P. Loyalka, B. Kar.
Enabled PRA and Precision PRA: Alternatives to cPRA as Desensitization Trial Endpoints.

E. Woodle, M. Pando Rigal, S. Tremblay, A. Girnita.
End Stage Renal Disease (ESRD) Patients' Willingness to Accept Risks to Living Kidney Donors.

J. Gannon,¹ C. Thiessen,¹ K. Yu,¹ L. Skrip,¹ P. Reese,² E. Gordon,³ S. Kulkarni.¹
End Stage Renal Disease Patients Have a Skewed T Cell Receptor Vbeta Repertoire.

L. Huang,¹ A. Langerak,² I. Wolvers - Tettero,² R. Meijers,¹ C. Baan,¹ N. Litjens,¹ M. Betjes.¹
End-Stage Renal Disease Does Not Impair the Large-Scale Generation of Potent Alloantigen-Specific Regulatory T Cells for Immunotherapy.

N. Litjens, K. Boer, J. Zuijderwijk, M. Klepper, A. Peeters, W. Verschoor, R. Kraaijeveld, C. Baan, M. Betjes.
Endoscopic Polydimethylsiloxane Injection in Prevention of Recurrent Graft Pyelonephritis for Transplanted Kidney with Vesicoureteral Reflux.

L. Nison,¹ M. Hazzan,² P. Puech,³ S. Bouye.¹
Engineering a “Hybrid Thymus” to Promote Transplant Tolerance.

S. AlFadil,¹ M.-J. Kim,² M. Iglesias Lozano,¹ B. Oh,¹ W. Lee,¹ G. Brandacher,¹ T. Serworld,² G. Raimondi.¹
Enhanced Activation of Hemostasis During Kidney Transplantation in Patients on Dialysis Compared to Pre-Emptively Transplanted Patients.

T. van den berg, G. Nieuwenhuijs-Moeke, S. Bakker, R. Pol, T. Lisman.
Enhanced IL-6 Production Impedes Transplant Tolerance Induction in Lupus-Prone Mice.

B. Stocks, C. Wilson, M. Seto, A. Marshall, D. Moore.
Enhanced Natural Killer Responsiveness Is a Potent Cytotoxic Mechanism Associating to Kidney Allograft Dysfunction and Pathogenic Effects of Donor-Specific Antibodies (DSA).

P. Paul,^1,2 T. Legris,³ C. Picard,⁴ D. Todorova,^1,2 L. Lyonnet,¹ L. Daniel,⁵ B. Dussol,^3,6 V. Moal,³ H. Vacher Coponat,³ Y. Berland,³ F. Dignat-George,^1,2 S. Burtey.^2,3
Enhanced Recovery After Kidney Transplantation: 48 Hour Length of Stay in Living and Deceased Donor Transplant Recipients.

O. Ojogho, J. Mejia, S. Bani-Hani, B. Dieter, R. Carson.
Eomesodermin Expression by CD8+ Alloreactive T Cells in Human and Nonhuman Primate Allograft Recipients.

A. Perez-Gutierrez, L. Lu, A. Zahorchak, Y. Ono, A. Thomson, M. Ezzelarab.
Epidemiology of Surgical Site Infections After Liver Transplantation: 4 Year Prospective Study.

Y. Natori, R. Kassar, A. Iaboni, S. Hosseini-Moghaddam, D. Vu, S. Husain, E. Renner, C. Rotstein.
Epitope Load Is Predictive of De Novo Donor Specific Antibodies Occurrence in Renal Transplant Recipients After Conversion from Cyclosporine to Everolimus.

R. Snanoudj,¹ C. Suberbielle,² N. Kamar,³ E. Cassuto,⁴ S. Caillard,⁵ J.-L. Taupin,² D. Anglicheau,¹ C. Legendre,¹ A. Hertig,⁶ E. Rondeau.⁶
ER Stress and Loss of GRP78 Expression Provides a Link Between Renal Ischemia/Reperfusion Injury and the Urinary Metabolome.

C. van Kooten,¹ T. Pacchiarotta,² P. van der Pol,¹ J. de Fijter,¹ N. Schlagwein,¹ D. van Gijlswijk,¹ O. Mayboroda.²
Erythropoietin (EPO) Mediates Spontaneous Kidney Transplant Tolerance in Mice.

P. Cravedi,¹ C. Purroy,¹ J. Madsen,² R. Fairchild,³ T. Tanaka,³ W. Baldwin 3rd,³ A. Alessandrini,² P. Heeger.¹
ESAT-6 Inhibits Donor-Specific Memory CD8+ T Cell Generation and Alloimmune Responses.

Z. Dai,¹ H. Dai.²
ESM1 Gene Promotes Hepatocyte Proliferation Through NF-κB Signal Pathway.

J. Zhou, W. Ju, X. Jiao, X. Zhu, X. He.
Establishing a Learning Curve for Laparoscopic Living Donor Nephrectomy.

Z. Ahmed, R. Tamburrini, R. Uwechue, P. Chandak, F. Calder, N. Kessaris, N. Mamode.
Establishing the Relationship Between Receptor Occupancy, Serum Exposure and Pathway Inhibition by the Blocking, Non-Depleting Anti-CD40 Antibody CFZ533 to Inform Dose Selection in Clinical Transplantation.

P. Espie, J. Munz, T. Flandre, B. Haraldsson, P. Ulrich, J. Rush.
Establishment of SCID Pigs Cell Lines to Prevent Immunodeficiency Using RGEN System.

D.-H. Kim,¹ J.-S. Ahn,¹ S. Hwang,² J.-W. Lee.¹
Evaluating Associations Between Clinical and Psychosocial Risk Factors and Adverse Post-Transplant Events in High Risk Renal Transplant Recipients.

C. Yellman, D. Destiche, A. DeMers, I. Feurer, M. Via, C. Gamble, H. Schaefer.
Evaluating Delayed Graft Function After Kidney Transplantation as a Potential Surrogate Outcome.

S. Cramm, X. Luo, A. Massie, D. Segev.
Evaluating Posttransplant BKV-Specific T Cell Responses in Patients with Alemtuzumab Induction and Belatacept-Based Regimen.

M. McRae, T. How, A. Kirk, H. Xu.
Evaluating the Influence of Liver Donor and Recipient Race on Tacrolimus Dose Requirements.

J. Knorr, J. Vidal, V. Navarro, R. Zaki.
Evaluation According to Donor Source: 24-Month Results from Post-Hoc Analysis of the ELEVATE Study in Kidney Transplant Recipients.

J. de Fijter, H. Holdaas, P. Lopez, P. Bernhardt, D. Gaohong, J. Cruzado, M. van der Giet.
Evaluation of a Novel Global Immunity Assay to Predict Infections in Organ Transplant Recipients.

M. Mian, A. Humar, S. Keshwani, S. Husain, P. Ashton, S. Han, L. Singer, J. Kim, E. Renner, M. Bhat, D. Kumar.
Evaluation of a Risk-Stratified Induction Immunosuppression Protocol Utilizing Low-Dose Antithymocyte Globulin in Renal Transplantation.

A. Diamond, Z. Khawaja, M. Simpson, S.-C. Kung, M. Akoad, J. Pomposelli, E. Pomfret.
Evaluation of an Early Steroid Withdrawal Maintenance Regimen in African American Renal Transplant Recipients.

S. Gabardi, M. Kim, R. Alsheikh, K. Townsend, A. Chandraker.
Evaluation of Conformational Diversity of a Single HLA-I Molecule Coated on Single Antigen Beads: Potential Impact on Organ Allocation?

V. Jucaud, M. Ravindranath, P. Terasaki.
Evaluation of Dose Dependent Rabbit Anti-Thymocyte Globulin Induction in Risk-Stratified Kidney Transplant Recipients.

I. Gutman, M. Misel, D. McKay, A. Hemming, J. Kerr, K. Mekeel.
Evaluation of Long Term Outcome After Living Donor Liver Transplantation in Sequential 653 Recipients with or without Viral Infection: Is HBV & HCV Co-Infection Better Than the Monoinfection? A Single Center Retrospective Analysis.

H. Yang, A. Thorat, L. Jeng, C.-C. Yeh, T.-H. Chen, S.-C. Hsu, K.-S. Poon.
Evaluation of Patient-Reported Nonadherence with Tacrolimus Level Variability in Renal Transplant Recipients.

N. Parrish,¹ T. Kaiser,² A. McCann,¹ J. Aladimi,² J. Harris,³ A. Govil,² B. Abu Jawdeh,² G. Mogilishetty,² R. Alloway,² E. Woodle.²
Evaluation of Perioperative Anemia and Associated Transfusion Requirements in Adult Liver Transplant Recipients.

E. Aldag, P. Moghimi, R. Pedersen, A. Sahajpal, J. Clendenon, V. Gunabushanam, M. Irani, D. Kramer.
Evaluation of Polyomavirus (BK) Treatment and Clinical Outcomes in Pediatric Kidney Transplant Recipients: A >10 Year Single Center Retrospective Experience.

R. Liverman,¹ E. Kraus,¹ R. Garro,² B. Warshaw,² P. Winterberg,² R. George.²
Evaluation of Scoring Systems Predicting Patient Survival at Time of Kidney Transplantation.

O. Staeck, D. Khadzhynov, A. Kleinsteuber, L. Lehner, M. Duerr, K. Budde, F. Halleck.
Evaluation of T Cell Immunity in Elderly Solid Organ Transplant Recipients.

J. Schaenman,¹ Y. Korin,² T. Sidwell,² V. Groysberg,² E. Lum,¹ E. Huang,¹ S. Bunnapradist,¹ T. Pham,¹ G. Danovitch,¹ E. Reed.²
Evaluation of the Impact of the Implementation of a Specialty Pharmacy Program in the Treatment of Hepatitis C (HCV).

E. Aldag, T. Pedone, R. Pedersen, S. Besur, K. Safdar, A. Sahajpal.
Evaluation of the Long-Term Outcomes with Everolimus After Calcineurin Inhibitor Withdrawal: 36M Results of the H2304 and PROTECT Extension Studies.

L. Fischer,^1,2 J. Fung,¹ H. Metselaar,¹ G. Kaiser,^1,2 P. Schemmer,² P. Neuhaus,² G. Dong,³ P. Lopez,⁴ P. Bernhardt,⁴ H. Schlitt.²
Evaluation of the Major Adverse Cardiac Events Risk with Everolimus-Based Calcineurin Inhibitor Reduction or Withdrawal Regimen in Liver Transplant Recipients: 3-Year Post-Hoc Analysis of the Randomized H2304 Extension Study.

P. Bernhardt,¹ G. Dong,² P. Lopez,¹ G. Hustache,¹ G. Bader.¹
Evaluation of the Toxicity Profile of Proteasome Inhibitor-Based Therapy for Antibody Mediated Rejection.

A. Leino,¹ A. Lichvar,¹ B. Abu-Jawdeh,¹ A. Govil,¹ G. Mogilishetty,¹ M. Cardi,² J. Kremer,² M. Cuffy,¹ F. Paterno,¹ R. Alloway,¹ A. Shields,^1,2 E. Woodle.¹
Evaluation of the Utilization of Filgrastim in Kidney Transplant Recipients.

T. Poon,¹ C. Guerra.²
Everolimus (EVR) versus Mycophenolate Sodium (MPS) for Recipients of Kidney Transplants from Expanded Criteria Donors (ECD) Receiving Anti-Thymocyte Globulin (r-ATG) and Tacrolimus (TAC).

H. Tedesco-Silva,¹ C. Felipe,¹ A. Brigido,¹ A. Bessa,¹ M. Paula,¹ P. Ruppel,¹ M. Cristelli,¹ L. Viana,¹ G. Basso,¹ M. Franco,² W. Aguiar,¹ J. Medina-Pestana.¹
Everolimus Abrogates C5a and TGFβ Mediated Perycite-to-Myofibroblast Transition (PMT) Inhibiting Vascular Rarefaction.

G. Castellano, R. Franzin, A. Stasi, C. Divella, L. Gesualdo.
Everolimus and Low Dose Cyclosporine Immunosuppressive Regimen and Development of Anti HLA Donor Specific Antibodies.

E. Minetti,¹ L. Di Maria,¹ L. Caroti,¹ E. Buti,² P. Carta.¹
Everolimus Decline Anti-ABO Blood Type Antibody Titer in Desensitization for ABO Incompatible Kidney Transplantation.

Y. Wada, N. Fukuzawa, H. Harada.
Everolimus in Combination with Reduced Dose Tacrolimus Is Effective as a Prophylaxis of Acute Rejection in Low-to-Moderate Immunologic Risk De Novo Kidney Transplantation Patients.

Y. Qazi, F. Shihab, S. Mulgaonkar, K. MaCague, D. Patel.
Everolimus Plus Reduced-Exposure Cyclosporin versus Mycophenolic Acid Plus Cyclosporin: Seven-Year Follow-Up of Australia and New Zealand Kidney Transplant Recipients in the A2309 Study.

S. Chadban,¹ H. Pilmore,² G. Russ,³ J. Kanellis,⁴ S. Campbell,⁵ P. O'Connell,⁶ W. Lim,⁷ M. Lutherborrow,⁸ N. Kurstjens,⁸ R. Walker.⁹
Everolimus versus Mycophenolate Mofetil in Combination with Tacrolimus: A Propensity Score Matching Analysis in Liver Transplantation.

P. de Simone,¹ P. Carrai,¹ A. Precisi,² L. Coletti,¹ D. Ghinolfi,¹ F. Filipponi.¹
Everolimus with Low-Dose Tacrolimus vs. a Standard Immunosuppressive Regimen: Renal Histology at 6 Months in De Novo Renal Transplant Patients.

S. Yilmaz,¹ D. Shaffer,² F. Shihab,³ K. McCague,⁴ D. Patel,⁴ Y. Qazi,⁵ F. Vincenti.⁶
Everolimus/Low Tacrolimus(TAC) Compared to MPA/RegularTAC for Renal Transplantation in the Elderly Recipient – Preliminary Analysis of the nEverOld Trial.

E. David-Neto,¹ F. Agena,¹ F. Ramos,¹ A. Triboni,¹ M. Altona,² V. Coelho,² N. Galante,¹ F. Lemos.¹
Eversion Endarterectomy of the Deceased Donor Renal Artery to Prevent Kidney Discard.

M. Khan, K. Jones, H. El-Hennawy, A. Farney, J. Rogers, G. Orlando, R. Stratta.
Evolution of Body Composition and Associations to Glucose Metabolism During the First Year After Kidney Transplantation.

M. von Düring,¹ A. Hartmann,^1,2 J. Bollerslev,^2,4 A. Åsberg,^1,3 K. Godang,⁴ I. Eide,¹ D. Dahle,¹ T. Jenssen.^1,5
Evolution of Donor Nephrectomy: Long-Term Outcomes with Four Different Techniques Between 1963 and 2014 at a Single Institution.

O. Serrano,¹ A. Bangdiwala,² D. Vock,³ E. Minja,¹ A. Pugalendhi,¹ K. Yadav,¹ V. Kirchner,¹ W. Payne,¹ T. Dunn,¹ S. Chinnakotla,¹ E. Finger,¹ T. Pruett,¹ A. Matas,¹ R. Kandaswamy.¹
Evolving to Everolimus: A Safe and Effective Option for Pancreas Transplant.

S. Yeager, A. Carlson, C. Truax, N. Kenyon, F. Ahmed, J. Corbett, F. Shihab, L. Smith.
Ex Situ Perfusion of a Human Limb for 24 Hours.

N. Werner,¹ F. Alghanem,¹ S. Rakestraw,¹ B. Nicely,² A. Olszewksi,² S. Rudich,² A. Rojas-Pena,¹ J. Magee,¹ K. Ozer.³
Ex Vivo Expansion of Human Alloantigen-Reactive Regulatory T Cells Using Monocyte-Derived Dendritic Cells versus CD40L-Stimulated B Cells.

H. Zhang,¹ Y. Zhao,¹ L. Lu,¹ Q. Tang,² M. Ezzelarab,¹ A. Thomson.¹
Ex Vivo Perfusion of Porcine Forelimbs to Prolong Allowable Ischemia Time.

N. Krezdorn,¹ M. Kueckelhaus,² A. Dermietzel,² M. Alhefzi,¹ M. Aycart,¹ S. Fischer,³ T.-S. Win,¹ H. Kiwanuka,¹ E. Bueno,¹ B. Pomahac.¹
Ex-Vivo Normothermic Perfusion (EVNP) Attenuation of Kidney Ischemia-Reperfusion Injury (IRI): A Proposed Mechanism.

I. Palma,¹ S. Kabagambe,¹ Y. Smolin,¹ T. Boyer,¹ I. Palma,¹ O. Fiehn,² Y.-J. Chen,¹ J. Sageshima,¹ C. Santhanakrishnan,¹ C. Troppmann,¹ R. Perez.¹
Ex-Vivo Normothermic Perfusion for Assessment of High Risk Deceased Donor Kidneys for Transplantation.

S. Kabagambe, I. Palma, Y. Smolin, T. Boyer, I. Palma, J. Sageshima, C. Santhanakrishnan, C. Troppmann, J. McVicar, R. Perez.
Examining the Risk for Post-Transplant Viral Infections and Lymphoproliferative Disorder (PTLD) in Kidney Transplant Patients (Pts) Receiving Calcineurin Inhibitor-Based Immunosuppression (CNI-IS) Compared to Belatacept (CTLA4Ig).

B. Shin, J. Choi, J. Kahwaji, S. Ge, D. Thomas, A. Vo, O. Galera, R. Villicana, A. Peng, S. Jordan, M. Toyoda.
Excellent Results of Living-Related Renal Transplant Recipients Treated with High-Dose Mizoribine – Comparison of Taclorimus with CsA for Two Years Result by a Japanese Multicenter Study.

N. Yoshimura, K. Nishimura, K. Akioka, M. Shimazu, K. Nose, T. Nishioka, N. Nakamura, K. Uchida, T. Nakatani, H. Ushigome.
Exome Sequencing and HLA-Independent Prediction of Long-Term Kidney Allograft Function.

L. Mesnard,^1,3,6 T. Muthukumar,^2,9 M. Burbach,² C. Li,² H. Shang,⁴ D. Dadhania,^2,3 J. Lee,^2,3 V. Sharma,² J. Xiang,⁴ M. Carmagnat,⁵ C. Suberbielle,⁵ N. Ouali,⁶ E. Rondeau,^6,1 J. Friedewald,⁸ M. Abecassis,⁷ M. Suthanthiran,^2,9 F. Campagne.³
Exosome-Like Vesicles Released in Association with Tissue Injury Trigger Anti-LG3 Production.

M. Dieudé,^1,2,3 J. Turgeon,^1,3 B. Yang,^1,2,3 L. Pomerleau,^1,3 K. Hamelin,^1,3 S. Lan,^1,2,3 S. Qi,^1,3 D. Gingras,^1,3 W. Dhari,¹ A. Rivard,¹ M.-J. Hébert.^1,2,3
Exosomes Expressing Cardiac Self-Antigens (Myosin and Vimentin) and Immuno-Regulatory miRNA Induce Graft Rejection.

M. Sharma,^1,2 M. Gunasekaran,^1,2 Z. Xu,^1,2 N. Steward,¹ W. Liu,^1,2 N. Benshoff,¹ T. Mohanakumar.^1,2
Exosomes with Lung Associated Self-Antigens (Collagen V and K alpha 1 Tubulin): Role in Rejection Following Human Lung Transplantation.

M. Gunasekaran,^1,2 Z. Xu,^1,2 D. Nayak,^1,2 M. Sharma,^1,2 R. Hachem,¹ T. Mohanakumar.^1,2
Expansion of Anti-HLA Antibodies After Renal Transplantation and Prognosis in Those Which Fix C1q.

P. Ruiz-Esteban,¹ M. Gonzalez-Molina,¹ A. Caballero,² A. Torio,² M. Leon,³ E. Palma,¹ D. Burgos,¹ M. Cabello,¹ V. Lopez,¹ M. Rodriguez,⁴ D. Hernandez.¹
Expansion of Regulatory B-Cells and Their Potential Role in Transplantation Tolerance.

B. Amundsen, H. Deirawan, J. Kim, J. Markmann.
Experience of Short-Term Preemptive Treatment for Cytomegalovirus Infection in Seropositive Patients After Liver Transplantation – Ten Years Result of a Single Institution.

T.-J. Wu, Y.-C. Wang, C.-H. Cheng, T.-H. Wu, R.-S. Soong, C.-F. Lee, H.-S. Chou, K.-M. Chan, W.-C. Lee.
Experience Using a Discharge Calculator for Discharge Planning Post Liver Transplantation (OLT).

K. Kerepesi, A. Waby, K. Eid, J. Plescia, K. Zinn, K. Vass, B. Eghtesad, C. Miller, D. Kelly.
Exposure Analysis for the Composite Efficacy Endpoints in the US92 Phase 3 Kidney Transplantation Trial to Understand Center Effects.

F. Shihab, B. Kaplan, K. McCague, D. Patel, F. Vincenti.
Extraperitoneal Placement of the Kidney Prevents Graft Vascular Kinking or Rotation in Simultaneous Pancreas-Kidney Transplant (SPK).

M. Maraschio, A. Alcaraz, E. Giordano Segade.
Extreme Hyperoxia During Pre-Implant Normothermic Liver Perfusion (PINLiP) Is Associated with Post-Reperfusion Syndrome and Vasoplegia.

C. Watson, V. Kosmoliaptsis, L. Randle, M. Hamed, J. Klinck, A. Butler.